Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.38
+4.2%
$1.22
$0.86
$3.78
$300.75M0.313.27 million shs879,714 shs
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$5.60
-3.9%
$4.66
$3.50
$12.40
$344.76M1.411.09 million shs130,747 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.15
+1.3%
$1.20
$0.83
$5.39
$71.24M1.13716,257 shs41,093 shs
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$4.37
+6.2%
$5.58
$2.02
$10.37
$234.33M0.33377,089 shs223,061 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
+5.60%+2.33%+7.32%-16.98%-53.36%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-1.85%+10.84%+25.92%+21.21%+36.85%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
0.00%-5.04%-3.42%+10.78%-67.53%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-3.75%-8.46%-26.08%-33.50%+89.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.4052 of 5 stars
4.51.00.00.03.22.50.6
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
1.8297 of 5 stars
3.31.00.00.01.91.70.6
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.7073 of 5 stars
3.43.00.00.00.00.80.6
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
1.4817 of 5 stars
3.51.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44514.14% Upside
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
2.67
Moderate Buy$15.33173.81% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00686.03% Upside
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
3.00
Buy$10.00129.04% Upside

Current Analyst Ratings Breakdown

Latest PYXS, ALLO, GLUE, and TKNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$8.00
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K15,037.69N/AN/A$2.01 per share0.68
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$75.62M4.56N/AN/A$3.63 per share1.54
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.39N/AN/A$2.03 per share0.56
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
$37.74M6.18N/AN/A$1.55 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$72.70M$0.0870.07N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.59N/AN/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$26.75M-$0.48N/AN/AN/A-60.90%-28.48%-19.73%8/12/2025 (Estimated)

Latest PYXS, ALLO, GLUE, and TKNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.31N/AN/AN/A$7.23 millionN/A
8/13/2025Q2 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.36N/AN/AN/AN/AN/A
8/6/2025N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
5/8/2025Q1 2025
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million
5/8/2025Q1 2025
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
-$0.11-$0.09+$0.02-$0.09$9.41 million$9.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
N/A
5.61
5.61
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.75
7.75
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
0.17
5.64
4.71

Institutional Ownership

CompanyInstitutional Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
79.96%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
13.81%

Insider Ownership

CompanyInsider Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
6.50%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9061.51 million57.51 millionOptionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million55.38 millionOptionable
Alpha Teknova, Inc. stock logo
TKNO
Alpha Teknova
24053.44 million46.76 millionNot Optionable

Recent News About These Companies

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance
Teknova Reports First Quarter 2025 Financial Results
BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.38 +0.06 (+4.17%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Monte Rosa Therapeutics stock logo

Monte Rosa Therapeutics NASDAQ:GLUE

$5.60 -0.23 (-3.95%)
As of 11:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.14 +0.02 (+1.33%)
As of 11:15 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Alpha Teknova stock logo

Alpha Teknova NASDAQ:TKNO

$4.37 +0.26 (+6.23%)
As of 11:16 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.